RedHill Biopharma (NASDAQ:RDHL) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a report released on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Trading Down 1.6 %

Shares of RDHL opened at $5.28 on Monday. The firm has a 50-day moving average price of $6.28 and a 200 day moving average price of $31.46. RedHill Biopharma has a 52-week low of $5.20 and a 52-week high of $20.27.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC purchased a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma as of its most recent filing with the SEC. 7.20% of the stock is currently owned by institutional investors.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.